SINDAXEL 6mg / ml perfusive solution concentrate medication leaflet

L01CD01 paclitaxel • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Taxanes

Paclitaxel is a chemotherapy agent used in the treatment of various cancers, including breast, ovarian, and lung cancer. It works by inhibiting cell division, stabilizing microtubules, and preventing chromosome separation during mitosis.

The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as nausea, hair loss, or peripheral neuropathy. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, hair loss, and peripheral neuropathy. In rare cases, severe reactions such as myelosuppression or allergic reactions may occur. Patients should be informed of these risks before use.

General data about SINDAXEL 6mg / ml

Substance: paclitaxel

Date of last drug list: 01-06-2025

Commercial code: W64717005

Concentration: 6mg / ml

Pharmaceutical form: perfusive solution concentrate

Packing volume: 50ml

Product type: generic

Price: 356.24 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SINDAN-PHARMA S.R.L. - ROMANIA

Holder: TEVA B.V. - OLANDA

Number: 9154/2016/05

Shelf life: 3 years

Concentrations available for paclitaxel

5mg/ml, 6mg/ml

Other substances similar to paclitaxel

Compensation lists for SINDAXEL 6mg / ml TEVA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

356.24 RON

356.24 RON

0.00 RON